Apoptotic effect of fludarabine is independent of expression of IAPs in B-cell chronic lymphocytic leukemia

Apoptosis

Volumn 11, Issue 2, 2006, Pages 277-285

  Silva, K L ^a,b   Vasconcellos, D V ^a   De Paula Castro, E D ^a   Coelho, A M ^a   Linden, R ^b   Maia, R C ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Apoptosis; B CLL; c IAP1; c IAP2; Fludarabine; XIAP

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; LIPOCORTIN 5; PREDNISONE; RITUXIMAB; VINCRISTINE; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; AGED; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; BIOASSAY; BLOOD SAMPLING; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELLS, CULTURED; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; LEUKEMIA, B-CELL, CHRONIC; MALE; MIDDLE AGED; VIDARABINE;

INTRACISTERNAL A-PARTICLES;

EID: 33344464822     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10495-006-3560-5     Document Type: Article

References (71)

1. Caligaris-Cappio F. Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol 2003; 123: 380-388.
2. Guipaud O, Deriano L, Salin H, et al. B-cell chronic lymphocytic leukaemia: a polymorphic family unified by genomic features. The Lancet 2003; 4: 506-514.
3. nd eddition. New York: Marcel Dekker 2001: 63-80.
4. nd eddition. New York: Marcel Dekker 2001: 111-126.
5. Ferrajoli A, O'brien SM. Treatment of chronic lymphocytic leukemia. Semin Oncol 2004; 31: 60-65.
6. Keating MJ. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia. Semin Oncol 1990; 17: 49-62.
7. Johnson S, Smith AS, Löffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996; 347: 1432-1438.
8. Bergmann L. Present status of purine analogs in the therapy of chronic lymphocytic leukemias. Leukemia 1997; 11: S29-S34.
9. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and CHOP in 938 previoulsly untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001; 98: 2319-2325.
10. Leporrier M. Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia. Hematol J 2004; 5: 10-19.
11. Robertson LE, Hubb S, Meyn RE, et al. Induction of apoptotic cell death in chronic lymphocytic leulemia by 2-chloro-2′-deoxyadenosine and 9-β-d-arabinosyl-2-fluoroaenine. Blood 1993; 81: 143-150.
12. Yamaushi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001; 7: 3580-3589.
13. Plunkett W, Gandhi V, Huang P, et al. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol 1993; 20: 2-12.
14. Sampath D, Plunkett W. The role of c-jun kinase in the apoptotic response to nucleoside analogue-induced DNA damage. Cancer Res 2000; 60: 6408-6415.
15. Gandhi V, Plunkett W. Combination strategies for purine nucleoside analogues. In: Cheson BD, ed. Chronic lymphoid leukemias. 2nd edition. New York: Marcel Dekker 2001: 195-208.
16. Genini D, Adachi S, Chao Q, et al. Deoxyadenosine analogues induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000; 96: 3537-3543.
17. Rosenwald A, Chuang EY, Davis RE, et al. Fludarabine treatment of chronic lymphocytic leukemia patients induces a p53-dependent gene expression response. Blood 2004; 104: 1428-1434.
18. Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998; 91: 3379-3389.
19. Bromidge TJ, Turner DL, Howe DJ, Johnson SA, Rule SAJ. In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues - correlation with clinical course. Leukemia 1998; 12: 1230-1235.
20. Bosanquet AG, Johnson SA, Richards SM. Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by disc assay. Br J Haematol 1999; 106: 71-77.
21. Tosi P, Pellacani A, Zinzani PL, Magagnoli M, Visani G, Tura S. In vitro study of the combination gemcitabine + fludarabine on freshly isolated chronic lymphocytic leukemia cells. Haematologica 1999; 84: 793-798.
22. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 2001; 15: 875-890.
23. Bosanquet AG, Sturm I, Wieder T, et al. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia. Leukemia 2002; 16: 1035-1044.
24. Lacasse EC, Baird S, Korneluk RG, Mackenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998; 17: 3247-3259.
25. de Graaf AO, de Witte T, Jansen JH. Inhibitor of apoptosis proteins: New therapeutic targets in hematological cancer? Leukemia 2004; 18: 1751-1759.
26. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921.
27. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998; 58: 5315-5320.
28. Altieri DC, Marchisio PC, Marchisio C. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Investig 1999; 79: 1327-1333.
29. Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000; 96: 1921-1925.
30. Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000; 6: 1796-1803.
31. Datta R, Oki E, Endo K, Biedermann V, Ren J, Kufe D. XIAP regulates DNA damage-induced apoptosis downstream of caspase-9 cleavage. J Biol Chem 2000; 275: 31733-31738.
32. Sasaki H, Sheng Y, Kotsuji F, Tsang BK. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 2000; 60: 5659-5666.
33. Kamihira S, Yamada Y, Hirakata Y, et al. Aberrant expression of caspase cascade regulatory genes in adult T-cell leukaemia: survivin is an important determinant for prognosis. Br J Haematol 2001; 114: 63-69.
34. Mori N, Yamada Y, Hata T, et al. Expression of survivin in HTLV-I-infected T-cell lines and primary ATL cells. Biochem Biophys Res Commun 2001; 282: 1110-1113.
35. Carter BZ, Milella M, Altieri DC, Andreeff M. Cytokine-regulated expression of survivin in myeloid leukemia. Blood 2001; 97: 2784-2790.
36. Carter BZ, Kornblau SM, Tsao T, et al. Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or survivin does not affect cell survival or prognosis. Blood 2003; 102: 4179-4186.
37. Yang L, Cao Z, Yan H, Wood WC. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res 2003; 63: 6815-6824.
38. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198-206.
39. Binet JL, Catovsky D, Dighiero G. Chronic lymphocytic leukemia: recommendations for diagnosis staging and response criteria International Workshop on CLL. Ann Intern Med 1989; 110: 236-244.
40. Tosi P, Pellacani A, Zinzani PL, Magagnoli M, Visani G, Tura S. In vitro study of the combination gemcitabine + fludarabine on freshly isolated chronic lymphocytic leukemia cells. Haematologica 1999; 84: 794-798.
41. Oliveira GB, Pereira FG, Metze, K., Lorand-Metze, I. Spontaneous apoptosis in chronic lymphocytic leukemia and its relationship to clinical and cell kinetic parameters. Cytometry 2001; 46: 329-335.
42. Mathas S, Lietz A, Janz M, et al. Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood 2003; 102: 1028-1034.
43. Pettitt AR, Moran EC, Cawley JC. Homotypic interactions protect chronic lymphocytic leukemia cells from spontaneous death in vitro. Leuk Res 2001; 25: 1003-1012.
44. Kawasaki H, Toyoda M, Shinohara H, et al. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 2001; 91: 2026-2032.
45. Ferreira CG, Valk PVD, Span SW, et al. Assessment of IAPs inhibitor of apoptosis proteins as predictors of response to chemotherapy in advanced non-small cell lung cancer patients. Ann Oncol 2001a; 12: 799-805.
46. Ferreira CG, Valk PVD, Span SW, et al. Expression of XIAP (X-Linked Inhibitor of Apoptosis) as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clin Cancer Res 2001b; 7: 2468-2474.
47. Rai KR, Döhner H, Keating MJ, Montserrat E. Chronic lymphocytic leukemia: case-based session. Hematology (Am Soc Hematol Educ Program) 2001; 140-156.
48. Keating MJ, Chiorazzi N, Messmer B, et al. Biology and treatment of chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program) 2003; 153-175.
49. Sturm I, Bosanquet AG, Hermann S, Guner D, Dorken B, Daniel PT. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 2003; 10: 477-484.
50. Byrd JC, Peterson B, Piro L, et al. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB study 9211. Leukemia 2003; 17: 323-327.
51. Imoto I, Yang ZQ, Pimkhaokham A, et al. Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res 2001; 61: 6629-6634.
52. Imoto I, Tsuda H, Hirasawa A, et al. Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. Cancer Res 2002; 62: 4860-4866.
53. Hasegawa T, Suzuki K, Sakamoto C, et al. Expression of the inhibitor of apoptosis (IAP) family members in human neutrophils: up-regulation of cIAP2 by granulocyte colony-stimulating factor and overexpression of cIAP2 in chronic neutrophilic leukemia. Blood 2003; 101: 1164-1171.
54. Yamamoto K, Abe S, Nakagawa Y, et al. Expression of IAP family proteins in myelodysplastic syndromes transforming to overt leukemia. Leuk Res 2004; 28: 1203-1211.
55. Tamm I, Richter S, Scholz F, et al. XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. Hematol J 2004; 5: 489-495.
56. Munzert G, Kirchner D, Stobbe H, et al. Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/rel-regulated inhibitors of apoptosis. Blood 2002; 100: 3749-3756.
57. Liu SS, Tsang BK, Cheung AN, et al. Anti-apoptotic proteins, apoptotic and proliferative parameters and their prognostic significance in cervical carcinoma. Eur J Cancer 2001; 37: 1104-1110.
58. Nowak D, Boehrer S, Brieger A, et al. Upon drug-induced apoptosis in lymphoma cells X-linked inhibitor of apoptosis (XIAP) translocates from the cytosol to the nucleus. Leuk Lymphoma 2004; 45: 1429-1436.
59. Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 1997; 16: 6914-6925.
60. Schiemann WP, Rotzer D, Pfeifer WM, et al. Transforming growth factor-beta (TGF-beta)-resistant B cells from chronic lymphocytic leukemia patients contain recurrent mutations in the signal sequence of the type I TGF-beta receptor. Cancer Detect Prev 2004; 28: 57-64.
61. Sanz L, Garcia-Marco JA, Casanova B, et al. Bcl-2 family gene modulation during spontaneous apoptosis of B-chronic lymphocytic leukemia cells. Biochem Biophys Res Commun 2004; 315: 562-567.
62. Mathiasen IS & Jaattela M. Triggering caspase-independent cell death to combat cancer. Trends Mol Med 2002; 8: 212-220.
63. Lockshin RA, Zakeri Z. Caspase-independent cell deaths. Curr Opin Cell Biol 2002; 14: 727-733.
64. Guimarães CA, Linden R. Programmed cell death: Apoptosis and alternative deathstyles. Eur J Biochem 2004; 271: 1638-1650.
65. Plate JM, Petersen KS, Buckingham L, Shahidi H, Schofield CM. Gene expression in chronic lymphocytic leukemia B cells and changes during induction of apoptosis. Exp Hematol 2000; 28: 1214-1224.
66. Sanna MG, da Silva Correia J., Luo Y, et al. ILPIP, a novel antiapoptotic protein that enhances XIAP-mediated activation of JNK1 and protection against apoptosis. J Biol Chem 2002; 277: 30454-30462.
67. Schliep S, Decker T, Schneller F, Wagner H, Hacker G. Functional evaluation of the role of inhibitor of apoptosis proteins in chronic lymphocytic leukemia. Exp Hematol 2004; 32: 556-562.
68. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000; 96: 393-397.
69. Sasaki H, Sheng Y, Kotsuji F, Tsang BK. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 2000; 60: 5659-5666.
70. Notarbartolo M, Cervello M, Dusonchet L, Cusimano A, D'Alessandro N. Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel anti-apoptosis factors IAP (inhibitory of apoptosis proteins). Cancer Lett 2002; 180: 91-101.
71. Decker T, Oelsner M, Kreitman RJ, et al. Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins. Blood 2004; 103: 2718-2726.